Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.

The pharmacogenomics journal - 1 Apr 2010

Han Ji-Youn, Lee Geon Kook, Yoo Sun Young, Yoon Sung Jin, Cho Eun Young, Kim Heung Tae, Lee Jin Soo

Abstract excerpt

Irinotecan induces small ubiquitin-like modifier (SUMO)-1 conjugation to topoisomerase-I, leading to enhanced sensitivity to irinotecan. In this study, we genotyped SUMO1 and UBC9 polymorphisms in 147 non-small-cell lung cancer (NSCLC) treated with irinotecan chemotherapy to investigate the association between genotypes and tumor response rate. Immunohistochemistry for SUMO1 and UBC9 was performed in 42 tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to SUMO-1 Protein

Share to Survival Analysis

Share to Ubiquitin-Conjugating Enzyme UBC9

Share to Ubiquitin-Conjugating Enzymes

Share to Up-Regulation

Source

Identifiers

PMID: 19859084
DOI: 10.1038/tpj.2009.46

Genes

SUMO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.PMID 19859084Read ↗

The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.Semantic proximity Read ↗

UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.Semantic proximity Read ↗

[Genetic and epigenetic changes in colorectal cancer and genetic testing for personalized medicine].Semantic proximity Read ↗

Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.Semantic proximity Read ↗

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.Semantic proximity Read ↗

A genetic variant in CDKN2A/2B locus was associated with poor prognosis in patients with esophageal squamous cell carcinomaSemantic proximity Read ↗

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.Semantic proximity Read ↗

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.